Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Sarcoma 1Breast 1

Conditions

Ovarian Neoplasms 11Prostatic Neoplasms 7Fallopian Tube Neoplasms 5Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Neoplasm Metastasis 2Glioblastoma 2Carcinoma, Ovarian Epithelial 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Prostate Adenocarcinoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Lung Neoplasms 1Hemangiosarcoma 1Head and Neck Neoplasms 1Glioma 1Endometrial Neoplasms 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 38Bevacizumab 23Cyclophosphamide 22Standard of Care 18Blood Specimen Collection 17Carboplatin 16Paclitaxel 15Nivolumab 14Gemcitabine 14Pemetrexed 13Exercise 13Cisplatin 12atezolizumab 11Radiotherapy 11Fluorouracil 11Doxorubicin 11Surveys and Questionnaires 9Rituximab 9Oxaliplatin 9Magnetic Resonance Spectroscopy 9Leucovorin 9Cetuximab 9Biopsy 9130-nm albumin-bound paclitaxel 9durvalumab 8abemaciclib 8Docetaxel 8olaparib 7Temozolomide 7Prednisone 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × niraparib × 90 days × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT03768063 2026-04-28

IMbrella B

Hoffmann-La Roche

Phase 3 Active not recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

NCT06077877 2026-04-24

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

GlaxoSmithKline

Phase 1/2 Active not recruiting
42 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡